GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Payments to Suppliers for Goods and Services

Viracta Therapeutics (STU:RYIS) Payments to Suppliers for Goods and Services


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Payments to Suppliers for Goods and Services?

Payments to Suppliers for Goods and Services only applicable to companies reporting Cash Flow from Operations in direct method.


Viracta Therapeutics (STU:RYIS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Payments to Suppliers for Goods and Services
Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.